Extreme LDL-C concentration is associated with increased cardiovascular disease in women with homozygous familial hypercholesterolemia

被引:0
|
作者
Paquette, Martine [1 ]
Ruel, Isabelle [2 ]
Guay, Simon-Pierre [1 ,3 ]
Al-Baldawi, Zobaida [4 ]
Brisson, Diane [5 ]
Gaudet, Daniel [5 ]
Couture, Patrick [6 ]
Bergeron, Jean [6 ]
Hegele, Robert A. [7 ,8 ,9 ]
Francis, Gordon A. [10 ,11 ]
Sherman, Mark H. [12 ]
Mcpherson, Ruth [13 ,14 ]
Ransom, Thomas [15 ]
Brunham, Liam R. [10 ,11 ]
Mancini, John [16 ]
Mccrindle, Brian W. [17 ]
Latan, Lulia
Genest, Jacques [2 ]
Baass, Alexis [1 ,18 ,19 ]
机构
[1] Montreal Clin Res Inst, Lipids Nutr & Cardiovasc Prevent Clin, 110 Ave Des Pins Ouest, Montreal, PQ H2W1R7, Canada
[2] Res Inst McGill Univ Hlth Ctr, Montreal, PQ, Canada
[3] Univ Montreal, Dept Med, Div Endocrinol, Montreal, PQ, Canada
[4] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON, Canada
[5] ECOGENE 21 Clin & Translat Res Ctr, Chicoutimi, PQ, Canada
[6] Univ Laval, CHU Quebec, Dept Specialized Med, Lipid Clin, Quebec City, PQ, Canada
[7] Western Univ, Dept Med, Schulich Sch Med, London, ON, Canada
[8] Western Univ, Schulich Sch Med, Dept Biochem, London, ON, Canada
[9] Western Univ, Robarts Res Inst, London, ON, Canada
[10] Univ British Columbia, Ctr Heart Lung Innovat, Providence Hlth Care Res Inst, Vancouver, BC, Canada
[11] Univ British Columbia, Dept Med, Vancouver, BC, Canada
[12] McGill Univ, Hlth Ctr, Dept Endocrinol, Montreal, PQ, Canada
[13] Univ Ottawa, Heart Inst, Lipid Clin, Ottawa, ON, Canada
[14] Univ Ottawa, Heart Inst, Atherogenom Lab, Ottawa, ON, Canada
[15] Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada
[16] Univ British Columbia, Ctr Cardiovasc Innovat, Vancouver, BC, Canada
[17] Univ Toronto, Hosp Sick Children, Labatt Family Heart Ctr, Dept Pediat, Toronto, ON, Canada
[18] McGill Univ, Div Expt Med, Dept Med, Montreal, PQ, Canada
[19] McGill Univ, Dept Med, Div Med Biochem, Montreal, PQ, Canada
关键词
Homozygous; Familial hypercholesterolemia; LDL-C; Cardiovascular; Risk factors; PREVALENCE;
D O I
10.1016/j.jacl.2024.10.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is arare genetic disease of low- density lipoprotein cholesterol (LDL-C) metabolism. Despite the devastating effect of this disease on atherosclerotic cardiovascular health, the disease phenotype and severity are more heterogeneous than previously thought. The predictors of atherosclerotic cardiovascular disease (ASCVD) in HoFH patients have never been systematically studied. OBJECTIVE: To investigate the univariate and multivariate predictors of ASCVD in HoFH patients. METHODS: Patients from the Canadian HoFH Registry were included in the present retrospective longitudinal study. Data for these patients were collected using a standardized questionnaire between 2019 and 2022 in 19 academic sites across Canada. Predictors of ASCVD were evaluated using Cox proportional hazards models. RESULTS: Among 48 HoFH patients, 26 (54%) of them had at least 1 ASCVD event. The average age at baseline was 19 +/- 15 years and women represented 56% of the cohort. The independent predictors of ASCVD events were male sex (HR 2.57 [1.13-5.84]), diabetes (HR 16.22 [3.38-77.97]), and LDL-C above the median of 14.45 mmol/L (559 mg/dL) (HR 3.10 [1.24-7.76]). When performing subgroup analysis according to sex, the presence of LDL-C above the median was associated with a significantly higher probability of ASCVD (88% vs 43%, P = .005) in women, but not in men (100% at age 40 in both groups, P = .98). CONCLUSION: This study reported for the first time the univariate and multivariate predictors of ASCVD in HoFH patients. We demonstrate that predictors of ASCVD in HoFH differ in males and females with respect to LDL-C levels. (c) 2024 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:105 / 113
页数:9
相关论文
共 50 条
  • [21] The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
    Awad Alshahrani
    Naji Kholaif
    Mutaz Al-Khnifsawi
    Hawazen Zarif
    Moeber Mahzari
    Advances in Therapy, 2024, 41 : 837 - 846
  • [22] The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
    Alshahrani, Awad
    Kholaif, Naji
    Al-Khnifsawi, Mutaz
    Zarif, Hawazen
    Mahzari, Moeber
    ADVANCES IN THERAPY, 2024, 41 (02) : 837 - 846
  • [23] Familial hypercholesterolemia/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity
    Foody, JoAnne M.
    Vishwanath, Raghu
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (04) : 970 - 986
  • [24] Prevalence and clinical consequences of genetic variants associated with familial hypercholesterolemia and LDL-C lowering in a diverse patient population
    Dubois, Bethany
    Soper, Emily
    Turchin, Michael
    Belbin, Gillian
    Kenny, Eimear
    Abul-Husn, Noura
    GENETICS IN MEDICINE, 2022, 24 (03) : S71 - S71
  • [25] THE ASSOCIATIONS OF ACCUMULATIVE LDL-C WITH ACHILLES TENDON THICKENING AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN JAPANESE PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
    Michikura, Masahito
    Harada-Shiba, Mariko
    Makino, Hisashi
    Hoshiga, Masaaki
    ATHEROSCLEROSIS, 2024, 395
  • [26] Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia
    Menzin, Joseph
    Aggarwal, Jyoti
    Boatman, Brian
    Yu, Jeffrey
    Stern, Kevin
    Harrison, David J.
    Patel, Jeetvan G.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (12): : 1270 - +
  • [27] Longitudinal Evaluation and Assessment of Cardiovascular Disease in Patients With Homozygous Familial Hypercholesterolemia
    Kolansky, Daniel M.
    Cuchel, Marina
    Clark, Bernard J.
    Paridon, Steve
    McCrindle, Brian W.
    Wiegers, Susan E.
    Araujo, Luis
    Vohra, Yogesh
    Defesche, Joep C.
    Wilson, James M.
    Rader, Daniel J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2008, 102 (11): : 1438 - 1443
  • [28] Correction to: The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
    Awad Alshahrani
    Naji Kholaif
    Mutaz Al-Khnifsawi
    Hawazen Zarif
    Moeber Mahzari
    Advances in Therapy, 2024, 41 : 2083 - 2083
  • [29] Applying an LDL-C threshold-based approach to identify individuals with familial hypercholesterolemia
    Jasani, Reena
    Ahmad, Zahid
    Schneider, Ruth
    Tujardon, Carol
    Basit, Mujeeb
    Khera, Amit
    JOURNAL OF CLINICAL LIPIDOLOGY, 2022, 16 (04) : 508 - 515
  • [30] Efficacy and Safety of Mipomersen in Patients with Familial Hypercholesterolemia and Inadequately Controlled LDL-C Levels
    Ballantyne, Christie
    Catapano, Alberico L.
    Davidson, Michael
    Mittleman, Robert
    Moriarty, Patrick M.
    Santos, Raul D.
    Sensinger, Charlotte
    de Banerjee, Samarita
    Singleton, Walter
    Baker, Brenda F.
    Soran, Handrean
    Tsimikas, Sotorios
    Kastelein, John J.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36